Results 281 to 290 of about 17,428,143 (356)

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

open access: yesMolecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla   +10 more
wiley   +1 more source

ABC8 Consensus: Assessment by a German Group of Experts. [PDF]

open access: yesBreast Care (Basel)
Ditsch N   +14 more
europepmc   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

open access: yesMolecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li   +10 more
wiley   +1 more source

Clinical Practice and Survival Analysis of Third-Line Therapy in Patients with Metastatic Colorectal Cancer: A Single-Center Retrospective Study. [PDF]

open access: yesCancer Manag Res
Li Q   +13 more
europepmc   +1 more source

Real-World Outcomes With Inetetamab-Based Regimens for HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Analysis in China. [PDF]

open access: yesCancer Control
Zheng F   +16 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy